Medical device company CHF Solutions Inc. has priced an underwritten public offering to raise $10.8 million.
Eden Prairie, Minn.-based CHF, which develops cardiac and coronary disease products, is offering 146,607 class A units at $5.25 apiece. Each unit consists of one share, a series 1 warrant to purchase a share at that price, and a series 2 warrant to purchase a share at the price. The series 1 warrants will expire in five years, and the series 2 warrants will expire either 18 months from the date of the offering, or upon the U.S. Food and Drug Administration's approval of CHF Solutions' Aquadex FlexFlow fluid removal device in pediatric patients.
CHF Solutions is also offering 1,910,536 class B units also at $5.25 apiece. Each class B unit consists of one series G convertible preferred share, which is convertible into one share of common stock, plus a Series 1 warrant to purchase a common share, and a Series 2 warrant to purchase a share.
The offering is expected to close on March 12.
Ladenburg Thalmann & Co. Inc. acted as book-running manager for the offering.